Diagnostics
Todos Medical Ltd. and Orot+ announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe.
Graduation underscores the critical progress that T2MR® technology has made in the rapid diagnosis of bacterial infections and accelerating time to appropriate treatment
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.
Todos Medical Ltd. announced it has entered into a binding term sheet with HWH World Pte Ltd., a wholly-owned subsidiary of Singapore eDevelopment for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada.
The receptivadx can have meaningful impact on women struggling with unexplained infertility by giving them an answer to their infertility. Learn more here.
Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer
Selux Diagnostics, Inc. announced its selection to present a poster and participate in a panel discussion at IDWeek 2019 – the upcoming Infectious Diseases Society of America conference.
QuantuMDx Group appoints Neil Butler as a Non-Executive Director
Oncimmune Holdings plc welcomes the presentation of data by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.
65 Percent of Patients Remained on Active Surveillance for More than Four Years
PRESS RELEASES